Cite
HARVARD Citation
Mascarenhas, J. et al. (2019). Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leukemia & lymphoma. 60 (5), pp. 1343-1345. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Mascarenhas, J. et al. (2019). Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leukemia & lymphoma. 60 (5), pp. 1343-1345. [Online].